顺铂+5-氟尿嘧啶联合顺铂腹腔热灌注治疗晚期胃癌的疗效及安全性探究

Efficacy and sefaty of 5-fluorouracil+cisplatin and cisplatin hyperthermic intraperitoneal chemotherapy in advanced gastric cancer

目的研究顺铂+5-氟尿嘧啶(DF)化疗方案联合顺铂腹腔热灌注治疗晚期胃癌的疗效及安全性。方法将128例晚期胃癌患者按治疗方式的不同分为观察组65例和对照组63例,对照组接受DF静脉化疗方案,观察组接受DF静脉化疗联合顺铂腹腔热灌注化疗方案。比较两组患者近期疗效、临床受益反应、不良反应发生情况以及生存情况。结果观察组患者缓解率为67.69%(44/65),明显高于对照组的44.44%(28/63),差异有统计学意义(P﹤0.01)。观察组卡氏功能状态(KPS)评分增加≥20分患者比例高于对照组,差异有统计学意义(P﹤0.05)。观察组患者化学性腹膜炎发生率高于对照组,差异有统计学意义(P﹤0.05)。观察组患者无进展生存期(PFS)及总生存期(OS)均长于对照组,差异均有统计学意义(P﹤0.05)。结论对晚期胃癌患者采用DF方案联合顺铂腹腔热灌注化疗,可显著提高缓解率,改善患者临床受益率,且不良反应较少,是一种安全可靠的治疗方案。

Objective To study the efficacy and safety of 5-fluorouracil+cisplatin(DF)hyperthermic intraperitoneal chemotherapy in advanced gastric cancer.Method 128 patients with advanced gastric cancer were randomly divided into observation group(n=65)and control group(n=63).The control group was treated with DF intravenous chemotherapy,and the observation group was treated with cisplatin hyperthermic intraperitoneal chemotherapy based on the control group.The short-term therapeutic effect,clinical benefit rate,adverse event and survival were compared.Result There were significant differences for response rate[67.69%(44/65)vs 44.44%(28/63),P<0.01],percentage of patients with≥20 incresases of Karnofsky performance status(KPS)scores(P<0.05),incidence of chemical peritonitis(P<0.05),progression free survival(PFS)and overall survival(OS)(P<0.05).Conclusion DF and cisplatin hyperthermic intraperitoneal chemotherapy can significantly improve the response rate and clinical benefit rate of patients with advanced gastric cancer with lower adverse effect,which is a safe and reliable treatment regimen.